Lynparza (Olaparib Tablets) and Zykadia

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this interaction is not currently available.GENERALLY AVOID: Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of olaparib, which is primarily metabolized by the isoenzyme. In a drug interaction study with 57 patients, olaparib peak plasma concentration (Cmax) and systemic exposure (AUC) increased by approximately 1.4- and 2.7-fold, respectively, during coadministration with the potent CYP450 3A4 inhibitor itraconazole. Increased exposure to olaparib may increase the risk of adverse effects such as hematologic toxicity, nausea, vomiting, diarrhea, anorexia, dyspepsia, and abdominal pain or discomfort. MANAGEMENT: Concomitant use of olaparib with potent CYP450 3A4 inhibitors should be avoided whenever possible. If coadministration is required, olaparib dosage should be reduced to 150 mg twice daily. References Cerner Multum, Inc. "Australian Product Information." O 0 "Product Information. Lynparza (olaparib)." Astra-Zeneca Pharmaceuticals, Wilmington, DE. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

GENERALLY AVOID: Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of olaparib, which is primarily metabolized by the isoenzyme. In a drug interaction study with 57 patients, olaparib peak plasma concentration (Cmax) and systemic exposure (AUC) increased by approximately 1.4- and 2.7-fold, respectively, during coadministration with the potent CYP450 3A4 inhibitor itraconazole. Increased exposure to olaparib may increase the risk of adverse effects such as hematologic toxicity, nausea, vomiting, diarrhea, anorexia, dyspepsia, and abdominal pain or discomfort.

MANAGEMENT: Concomitant use of olaparib with potent CYP450 3A4 inhibitors should be avoided whenever possible. If coadministration is required, olaparib dosage should be reduced to 150 mg twice daily.

Lynparza (Olaparib Tablets)

Generic Name: olaparib

Brand name: Lynparza

Synonyms: Lynparza

What is Lynparza (Olaparib Tablets)?

Zykadia

Generic Name: ceritinib

Brand name: Zykadia

Synonyms: n.a.

What is Zykadia?